118 related articles for article (PubMed ID: 3522312)
1. The steady-state pharmacokinetics of tamoxifen and its metabolites in breast cancer patients.
Soininen K; Kleimola T; Elomaa I; Salmo M; Rissanen P
J Int Med Res; 1986; 14(3):162-5. PubMed ID: 3522312
[TBL] [Abstract][Full Text] [Related]
2. Serum and urine levels of tamoxifen and its metabolites in patients with advanced breast cancer after a loading dose and at steady-state levels.
de Vos D; Slee PH; Briggs RJ; Stevenson D
Cancer Chemother Pharmacol; 1998; 42(6):512-4. PubMed ID: 9788580
[TBL] [Abstract][Full Text] [Related]
3. Analysis of phase I and phase II metabolites of tamoxifen in breast cancer patients.
Poon GK; Chui YC; McCague R; Lłnning PE; Feng R; Rowlands MG; Jarman M
Drug Metab Dispos; 1993; 21(6):1119-24. PubMed ID: 7905393
[TBL] [Abstract][Full Text] [Related]
4. Identification of tamoxifen metabolites in human Hep G2 cell line, human liver homogenate, and patients on long-term therapy for breast cancer.
Poon GK; Walter B; Lønning PE; Horton MN; McCague R
Drug Metab Dispos; 1995 Mar; 23(3):377-82. PubMed ID: 7628304
[TBL] [Abstract][Full Text] [Related]
5. Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment.
Lien EA; Solheim E; Lea OA; Lundgren S; Kvinnsland S; Ueland PM
Cancer Res; 1989 Apr; 49(8):2175-83. PubMed ID: 2702659
[TBL] [Abstract][Full Text] [Related]
6. Implications of tamoxifen metabolism in the athymic mouse for the study of antitumor effects upon human breast cancer xenografts.
Robinson SP; Langan-Fahey SM; Jordan VC
Eur J Cancer Clin Oncol; 1989 Dec; 25(12):1769-76. PubMed ID: 2632258
[TBL] [Abstract][Full Text] [Related]
7. Comparative binding affinities of tamoxifen, 4-hydroxytamoxifen, and desmethyltamoxifen for estrogen receptors isolated from human breast carcinoma: correlation with blood levels in patients with metastatic breast cancer.
Fabian C; Tilzer L; Sternson L
Biopharm Drug Dispos; 1981; 2(4):381-90. PubMed ID: 7317574
[TBL] [Abstract][Full Text] [Related]
8. Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer.
Langan-Fahey SM; Tormey DC; Jordan VC
Eur J Cancer; 1990; 26(8):883-8. PubMed ID: 2145931
[TBL] [Abstract][Full Text] [Related]
9. Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide.
Lien EA; Anker G; Lønning PE; Solheim E; Ueland PM
Cancer Res; 1990 Sep; 50(18):5851-7. PubMed ID: 2393854
[TBL] [Abstract][Full Text] [Related]
10. Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients.
Lien EA; Wester K; Lønning PE; Solheim E; Ueland PM
Br J Cancer; 1991 Apr; 63(4):641-5. PubMed ID: 2021551
[TBL] [Abstract][Full Text] [Related]
11. Identification and biological activity of tamoxifen metabolites in human serum.
Kemp JV; Adam HK; Wakeling AE; Slater R
Biochem Pharmacol; 1983 Jul; 32(13):2045-52. PubMed ID: 6870933
[TBL] [Abstract][Full Text] [Related]
12. Excretion of hydroxylated metabolites of tamoxifen in human bile and urine.
Kisanga ER; Mellgren G; Lien EA
Anticancer Res; 2005; 25(6C):4487-92. PubMed ID: 16334131
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacology of tamoxifen and N-desmethyltamoxifen in patients with advanced breast cancer.
Wilkinson P; Ribeiro G; Adam H; Patterson J
Cancer Chemother Pharmacol; 1980; 5(2):109-11. PubMed ID: 7471314
[TBL] [Abstract][Full Text] [Related]
14. Optimised analysis of tamoxifen and its main metabolites in the plasma and cytosol of mammary tumours.
Milano G; Etienne MC; Frenay M; Khater R; Formento JL; Renee N; Moll JL; Francoual M; Berto M; Namer M
Br J Cancer; 1987 May; 55(5):509-12. PubMed ID: 3606944
[TBL] [Abstract][Full Text] [Related]
15. Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient.
Robinson SP; Langan-Fahey SM; Johnson DA; Jordan VC
Drug Metab Dispos; 1991; 19(1):36-43. PubMed ID: 1673419
[TBL] [Abstract][Full Text] [Related]
16. Tamoxifen and its main metabolites serum and tissue concentrations in breast cancer women.
Furlanut M; Franceschi L; Pasqual E; Bacchetti S; Poz D; Giorda G; Cagol P
Ther Drug Monit; 2007 Jun; 29(3):349-52. PubMed ID: 17529893
[TBL] [Abstract][Full Text] [Related]
17. Determination and pharmacology of a new hydroxylated metabolite of tamoxifen observed in patient sera during therapy for advanced breast cancer.
Jordan VC; Bain RR; Brown RR; Gosden B; Santos MA
Cancer Res; 1983 Mar; 43(3):1446-50. PubMed ID: 6825112
[TBL] [Abstract][Full Text] [Related]
18. Analysis of tamoxifen and its metabolites in human plasma by gas chromatography-mass spectrometry (GC-MS) using selected ion monitoring (SIM).
Murphy C; Fotsis T; Pantzar P; Adlercreutz H; Martin F
J Steroid Biochem; 1987 May; 26(5):547-55. PubMed ID: 3586671
[TBL] [Abstract][Full Text] [Related]
19. Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment.
Lien EA; Solheim E; Ueland PM
Cancer Res; 1991 Sep; 51(18):4837-44. PubMed ID: 1893376
[TBL] [Abstract][Full Text] [Related]
20. [Steady state and disappearance of the metabolites of miproxifene phosphate in the treatment of breast cancer].
Morimoto K; Abe O; Kinoshita H
Gan To Kagaku Ryoho; 1998 Aug; 25(10):1565-73. PubMed ID: 9725050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
